HeartSciences Announces Passing of COO and Director Mark Hilz; Role Not to Be Replaced
HSCS sits 17% above its 52-week low of $2.01.
Summary
HeartSciences Inc. announced the death of its Chief Operating Officer and Director, Mark Hilz, stating the role will not be replaced and no operational impact is expected.
Key Events · Executive and Board Changes · HSCS
-
COO and Director Passes Away
Mark Hilz, Chief Operating Officer, Corporate Secretary, and a member of the Board of Directors of HeartSciences Inc., passed away on April 1, 2026, at the age of 67.
-
Long-Serving Executive
Mr. Hilz served on the Board of Directors since 2013 and as Chief Operating Officer and Corporate Secretary since March 2022.
-
Role Not to Be Replaced
The company does not anticipate hiring a new Chief Operating Officer or replacing the role in the foreseeable future, citing the launch of its MyoVista Insights™ platform and FDA submission.
-
No Anticipated Operational Impact
HeartSciences Inc. states it does not anticipate any changes to its business, operations, or planned commercialization of the MyoVista Insights platform as a result of Mr. Hilz's passing.
Analysis · HSCS · Industrial Applications And Services
HeartSciences Inc. reported the passing of Mark Hilz, its Chief Operating Officer, Corporate Secretary, and a long-standing member of the Board of Directors. Mr. Hilz had served on the Board since 2013 and in his executive roles since March 2022. While the company stated it does not anticipate replacing the COO role or any changes to its business operations or commercialization plans, the loss of a key executive, particularly in a micro-cap company that recently issued a going concern warning, adds to concerns about leadership stability and operational continuity. The decision not to replace the role could be interpreted as a strategic adjustment or a reflection of financial constraints.
At the time of this filing, HSCS was trading at $2.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $2.01 to $6.47. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.